

Announcement & Programme

THNO

9th Trends in Head & Neck Oncology

November 9-11, 2023

NH Hotels Málaga, Spain



www.thno2023.org

Important Dates & Venue

30 June 2023
15 September 2023
Late September 2023
15 October 2023

Deadline early registration fee
Abstract deadline
Confirmation of abstract acceptance
Deadline regular registration fee

Venue

NH-Hotel Málaga
C/ San Jacinto 2
29007 Málaga
SPAIN
T. +34-952071323
www.nh-hotels.com/hotel/nh-malaga

The 9th Trends in Head & Neck Oncology is endorsed by:



Endorsed by ¹
ESTRO

The 9th Trends in Head & Neck Oncology is sponsored by:



Visit the Congress website to obtain the latest information:

www.THNO2023.org

Congress secretariat

Congress Care 
P.O. Box 440
5201 AK 's-Hertogenbosch
The Netherlands
Tel +31-73-690-1415
registrations@congresscare.com
www.congresscare.com

Invitation & scientific committee

Dear colleagues and friends,

It is with great pleasure that we invite you to attend the 9th Trends in Head & Neck Oncology (THNO-9) meeting, which will be held face-to-face in Málaga, Spain, on November 9 – 11, 2023.

With a wealth of exciting new data emerging both from the laboratory and the clinic in this rapidly evolving field, THNO-9 will highlight innovations in the three traditional pillars of treatment, i.e., surgery, radiation, and chemotherapy, and will give relevant updates on the fourth pillar: immunotherapy. Multidisciplinary decision making during multidisciplinary team meetings is key in daily practice, taking into account practical guidelines that are being updated regularly. We will discuss active research in a number of emerging areas such as: potentially malignant disorders of the oral region, the role of artificial intelligence, innovations in cell-based assays for drug discovery and drug evaluation, the role of genomics and beyond in precision medicine, mechanism of action and potential use of SMAC mimetics, and the potential roles of antibody-drug conjugates in head & neck cancer. We will also address innovations in treatment and management including: intratumoral drug administration and metronomic chemotherapy with or without low dose immune checkpoint inhibitors, optimal local treatment in patients with metastatic head & neck cancer, sentinel node biopsy in cN0 early stage oral cavity cancer, partial laryngectomy, improving quality of reconstructive surgery, innovations in radiotherapy, such as proton therapy, FLASH therapy, and several ways to overcome hypoxia-induced (radio)resistance. Finally, in a separate session, the molecular characterization and its impact on treatment of salivary gland cancers and strategies how to improve outcome in salivary duct carcinoma will be highlighted.

All disciplines involved in the treatment of head & neck cancer will be represented in integrated sessions. The translation to daily practice will be brought to the spotlight by interactive clinical case discussions facilitated by panels. The THNO-9 meeting is designed for all medical oncologists, surgeons, radiation oncologists, otolaryngologists, and other medical professionals involved in the treatment of patients with head & neck cancer.

The THNO-9 face-to-face meeting will offer you excellent science and medicine in the beautiful city of Málaga.

We look forward to welcoming you in Málaga!

Meeting chairs & scientific committee

Jan B. Vermorken, Edegem, Belgium

Hans Langendijk, Groningen, The Netherlands

René Leemans, Amsterdam, The Netherlands

Jean-Pascal Machiels, Brussels, Belgium

Piero Nicolai, Brescia, Italy

Brian O'Sullivan, Toronto, Canada

Scientific Programme

Thursday, November 9, 2023

Session: From basic science to clinical application

Chair: Jan B. Vermorken (BE)

12.30 Welcome

13:00 Oral potentially malignant disorders (OPMD): an update
Ruud Brakenhoff (NL)

13:25 The role of artificial intelligence in OPMD
Pierre Saintigny (F)

13:50 Treatment of OPMD and first results of immune checkpoint inhibitors
Paolo Bossi (I)

14:15 Innovations in cell-based assays for drug discovery and drug evaluation
Ingeborg Tinhofer (DE)

14:40 Break and poster viewing

15:10 Is the ESCAT ranking of support in head and neck cancer management?
Maud Kamal (F)

15:35 Mechanism of action and potential use of SMAC mimetics in HNSCC
Ben O'Leary (UK)

16:00 Precision medicine beyond genomics
Enrique Sanz (CA)

16:25 **Proffered paper session 1** (chaired by René Leemans (NL))

17:30 **Clinical cases: Panel discussion** (chaired by Brian O'Sullivan (CA))
Panel: René Leemans, Piero Nicolai, Maria Isabel Falguera Uceda, Hans Langendijk, Jorge Contreras, Jean-Pascal Machiels, Antonio Rueda, Marc Oliva, Almudena Pérez Lara, Paolo Bossi

19:00 Welcome reception

Friday, November 10, 2023

Session Primary disease (1)

Chair: Hans Langendijk (NL)

08:30 Sentinel Node Biopsy in cN0 Early-Stage Oral Cavity Cancer: what is the evidence?
Clare Schilling (UK)

09:55 Partial laryngeal surgery in 2023
Giovanni Succo (I)

09:20 Managing the internal carotid artery in head and neck cancer: where are we?
Piero Nicolai (I)

Scientific Programme

- 09:45 Improving quality of reconstructive surgery in head and neck cancer
Sat Parmar (UK)
- 10:10 Coffee break and poster viewing**
- 10:45 Innovation in radiotherapy: "FLASH-therapy"
Jean Bourhis (CH)
- 11:10 Hypoxia in head and neck cancer: current relevance
Olivier Feron (BE)
- 11:35 Hyperthermia: a game changer in the management of head and neck cancer?
Anthony Kong (UK)
- 12:00 **Clinical cases: Panel discussion** (chaired by *Piero Nicolai (I)*)
Panel: *René Leemans, Carlos Chiesa, María Isabel Falguera Uceda, Jean-Pascal Machiels, Antonio Rueda, Marc Oliva, Kevin Harrington, Jorge Contreras, Almudena Pérez Lara, Petr Szturz*
- 13:30 Lunch and poster viewing**
- Session Primary disease (2)**
Chair: *Piero Nicolai (I)*
- 14:30 Prognostic factors in HPV-positive oropharyngeal cancer: an update
Brian O'Sullivan (CA)
- 14:55 Immunotherapy and novel agents in locoregionally advanced HNSCC
Jean-Pascal Machiels (BE)
- 15:20 Is reducing the extent of local treatments justified after successful neoadjuvant therapy?
Andreas Dietz (DE)
- 15:45 Noninvasive biomarkers predicting outcome in patients with locoregionally advanced HNSCC
Ricard Mesia (ES)
- 16:10 Coffee break**
- 16:40 Innovations in head and neck surgery in the 21st century
René Leemans (NL)
- 17:05 Impact of emerging technology developments in proton therapy.
Hans Langendijk (NL)
- 17:30 **Proffered paper session 2** (chaired by *Jean-Pascal Machiels (BE)*)
- 18:30 **Debate** (moderator *Jan Vermorken (BE)*)
This house believes that hypoxic modification should be used to enhance the effect of (chemo)radiation in patients with locoregionally advanced HNSCC
Pro-position: *Jens Overgaard (DK)* (seconded by *Jean Bourhis (CH)*)
Contra-position: *Vincent Gregoire (F)* (seconded by *Hans Langendijk (NL)*)

Scientific Programme

Saturday, November 11, 2023

Session Recurrent/Metastatic (R/M) disease

Chair: Brian O'Sullivan (CA)

- 08:30 50 years of systemic therapy: what have we gained?
Jan Vermorken (BE)
- 08:55 The potential roles of Antibody-Drug Conjugates in head and neck cancer
Christophe Le Tourneau (F)
- 09:20 Intratumoral drug administration: more potential in head and neck cancer?
Kevin Harrington (UK)

09:45 Sponsored lecture (Nanobiotix)

Novel radioenhancer NBTXR3 as a single agent in locally advanced (LA) HNSCC or in combination with anti-PD1 in R/M HNSCC
Jean Bourhis (CH)

10:10 Coffee break

- 10:45 Metronomic chemotherapy and immunotherapy: a fascinating approach
Kumar Prabhash (IN)
- 11:10 Metastatic head and neck cancer: what is the optimal local treatment?
Petr Szturz (CH)

Session Salivary Gland cancer

- 11:35 Molecular characterization of salivary gland cancer and treatment implications
Alberto Hernando (ES)
- 12:00 Salivary duct carcinoma: strategies to improve outcome
Lisa Licitra (I)
- 12:25 General discussion
- 13:00 Adjourn**

Accreditation

Accreditation will be applied for at the European Accreditation Council for Continuing Medical Education (EACCME). This accreditation will be endorsed by the European Union of Medical Specialists (UEMS) ensuring that the CME credits awarded to the participants are recognized by the national medical authorities who have agreed to co-operate in this European system. EACCME credits are recognized by the American Medical Association towards the Physician's Recognition Award (PRA). The previous THNO edition was granted with 14 European CME credits.

General Information

Call for abstracts

The scientific committee would like to encourage authors to submit their abstracts through the website www.thno2023.org.

Abstracts can be submitted for oral or poster presentations.

Abstract submission deadline: 15 September 2023 Letters of acceptance will be mailed by Late September 2023

Registration fees

The 9th Trends in Head & Neck Oncology (THNO-9) meeting will be held **face to face** in Málaga, Spain.

Until 30 June 2023: EUR 295

1 July 2023 - 15 October 2023 EUR 395

After 15 October 2023 and on-site EUR 495

What is included in the registration fee?

Admission to the meeting, welcome reception, programme and abstract book, certificate of attendance, lunch and coffee breaks.

Hotel accommodation

The organization of THNO 2023 has secured a number of rooms in the THNO congress venue: NH-Hotel Málaga, Spain. You can book your hotel accommodation directly at the hotel. A booking link will be available at the congress website. Please note: limited availability.

Single room EUR 160* per night

Double room EUR 170* per night

**Including breakfast, VAT and city tax*

How to register and pay

Please register online through the website www.THNO2023.org.

Online payment is possible (Mastercard, VISA, American Express).

Group registrations

For group registrations; please contact the congress secretariat via: registrations@congresscare.com, before starting your group registration.

Cancellation

Cancellations and refund requests must be submitted in writing to the congress secretariat. Cancellations made before 1 September 2023 will be refunded, minus 30% to cover administration costs. After this date no refunds will be given. All refunds will be made after the congress.

Exhibition & sponsored symposia

A targeted group of biotechnical and pharmaceutical will be invited to organize a sponsored symposium and/or exhibit their products and services.



www.THNO2023.org